From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for ...

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its ...